Printer Friendly

Abzyme Files Patent Application for Self-Diversifying Antibody Platform.

Royersford, PA, August 03, 2017 --(PR.com)-- Abzyme Therapeutics LLC, a biotechnology company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled "Composition and Method for Diversifying Polypeptide Libraries," USPTO number 62/387,511. This is an important milestone for Abzyme Therapeutics in protecting its intellectual property and solidifying its IP position as a leader in the field of antibody engineering and development. The invention provides a method and composition for diversifying polypeptide libraries displayed on the surface of yeast cells. The antibody library built in this self-diversifying platform has potentially unlimited diversity. One application of this technology is in vivo rapid generation of therapeutic antibody candidates with desired attributes. It can also be used for maturation of existing antibodies to achieve higher target binding affinity or protein expressibility.

As provided by this invention, a polypeptide library is displayed on the cell surfaces of a highly engineered yeast strain. The yeast strain incorporates an inducible hypermutation system that exclusively introduces base substitutions into a gene of interest. In combination with biological panning, an antibody molecule displayed on the yeast cell surface sequentially undergoes diversification followed by affinity selection to achieve higher binding affinity to a target of interest. Using this technology platform, Abzyme develops various types of antibodies including, but not limited to camelid and human single domain antibodies, human ScFv and full human IgG.

"Filing this application is very important milestone for Abzyme Therapeutics. This patent application further solidifies our IP position in the field of antibody development and engineering," said Dr. Tran, CEO and co-founder of Abzyme. "We use this technology every day to generate therapeutic antibody candidates to difficult targets including non-immunogenic or toxic antigens. This invention actually makes work easier and significantly faster in discovering antibodies with desired therapeutic attributes."

For further information, please contact:

Abzyme Therapeutics LLC

www.abzymetx.com

Stephen Manobianco

Director of Business Development

Phone: 610-990-7531

E-mail: manobianco@abzymetx.com

Contact Information:

Abzyme Therapeutics LLC

Hiep Tran

610-990-7531

Contact via Email

www.abzymetx.com

Read the full story here: http://www.pr.com/press-release/725429

COPYRIGHT 2017 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Date:Aug 3, 2017
Words:348
Previous Article:DISA Global Solutions (DISA) and iCIMS Announce Partnership to Help Recruiters Streamline Their Employee Screening and Talent Acquisition Processes.
Next Article:Local Salon Partners with Denver School of Botanical and Medical Aesthetics to Help Students Meet Required Practical Hours.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters